Andrew Marsh

Andrew Marsh has a diverse and extensive work experience in the clinical development and operations field. Andrew is currently serving as the Vice President of Clinical Development Operations at Mariana Oncology since February 2023. Previously, they worked as a Clinical Development Consultant and later as the Vice President of Clinical Development Operations at Vigil Neuroscience from June 2021 to July 2022. Before that, they held the position of Vice President and Head of Development Operations at Synlogic, Inc. from June 2020 to May 2021. Andrew also has experience working at Ra Pharmaceuticals as an Executive Director of Clinical Development and as a Senior Director and Head of Clinical Operations between October 2016 and May 2020. Additionally, they have worked at other esteemed companies such as Onkaido Therapeutics, Tetraphase Pharmaceuticals, Ziopharm Oncology, Antisoma, Xanthus Pharmaceuticals, and Perceptive Informatics (PAREXEL), holding various roles in clinical operations and project management throughout their career.

Andrew Marsh earned a Bachelor of Science (BS) degree in Biomedical Engineering from Boston University between 2000 and 2004.